| PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma (NCT04303117) | National Cancer Institute (NCI) | 2020-07-13 |
| Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (NCT04310007) | National Cancer Institute (NCI) | 2020-07-13 |
| Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (NCT04216329) | National Cancer Institute (NCI) | 2020-07-07 |
| E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer (NCT04015336) | National Cancer Institute (NCI) | 2020-07-06 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (NCT04197713) | National Cancer Institute (NCI) | 2020-06-30 |
| Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) (NCT04447014) | National Cancer Institute (NCI) | 2020-06-25 |
| Testing the Safety of CB-5339 in Patients With Cancer (NCT04372641) | National Cancer Institute (NCI) | 2020-06-18 |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (NCT03939897) | National Cancer Institute (NCI) | 2020-06-17 |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (NCT04267848) | National Cancer Institute (NCI) | 2020-06-16 |
| Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis (NCT04034251) | National Cancer Institute (NCI) | 2020-06-09 |
| Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies (NCT04287868) | National Cancer Institute (NCI) | 2020-06-09 |
| Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection (NCT04247282) | National Cancer Institute (NCI) | 2020-06-09 |
| NCI COVID-19 in Cancer Patients, NCCAPS Study (NCT04387656) | National Cancer Institute (NCI) | 2020-06-05 |
| Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation (NCT04428918) | National Cancer Institute (NCI) | 2020-06-05 |
| Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors (NCT04074135) | National Cancer Institute (NCI) | 2020-06-02 |
| E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia (NCT04411134) | National Cancer Institute (NCI) | 2020-05-28 |
| Tocilizumab for Patients With Cancer and COVID-19 Disease (NCT04370834) | National Cancer Institute (NCI) | 2020-05-28 |
| Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma (NCT04150562) | National Cancer Institute (NCI) | 2020-05-26 |
| Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies (NCT04266093) | National Cancer Institute (NCI) | 2020-05-08 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (NCT04092270) | National Cancer Institute (NCI) | 2020-05-07 |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia (NCT03983824) | National Cancer Institute (NCI) | 2020-05-05 |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NCT04092283) | National Cancer Institute (NCI) | 2020-04-29 |
| Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection (NCT04362865) | National Cancer Institute (NCI) | 2020-04-27 |
| Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) (NCT04358107) | National Cancer Institute (NCI) | 2020-04-20 |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy (NCT03965689) | National Cancer Institute (NCI) | 2020-04-16 |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer (NCT04214067) | National Cancer Institute (NCI) | 2020-04-09 |
| PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers (NCT04209595) | National Cancer Institute (NCI) | 2020-04-08 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (NCT04068194) | National Cancer Institute (NCI) | 2020-04-07 |
| Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NCT04164082) | National Cancer Institute (NCI) | 2020-03-18 |
| Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer (NCT03831932) | National Cancer Institute (NCI) | 2020-03-16 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver (NCT04175912) | National Cancer Institute (NCI) | 2020-03-16 |
| Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral (NCT04025567) | National Cancer Institute (NCI) | 2020-03-12 |
| Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia (NCT04277442) | National Cancer Institute (NCI) | 2020-03-11 |
| Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer (NCT03478904) | National Cancer Institute (NCI) | 2020-03-10 |
| Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement (NCT03701295) | National Cancer Institute (NCI) | 2020-03-06 |
| Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome (NCT04185220) | National Cancer Institute (NCI) | 2020-02-26 |
| Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma (NCT03919071) | National Cancer Institute (NCI) | 2020-02-20 |
| Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment (NCT03770260) | National Cancer Institute (NCI) | 2020-02-10 |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (NCT03914300) | National Cancer Institute (NCI) | 2020-02-10 |
| A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (NCT04166409) | National Cancer Institute (NCI) | 2020-01-31 |
| Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors (NCT03878095) | National Cancer Institute (NCI) | 2020-01-30 |
| M7824 Related Adverse Effects in Adults With Cancer (NCT04267861) | National Cancer Institute (NCI) | 2020-01-28 |
| Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma (NCT03727841) | National Cancer Institute (NCI) | 2020-01-22 |
| A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma (NCT03871257) | National Cancer Institute (NCI) | 2020-01-15 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (NCT02923778) | National Cancer Institute (NCI) | 2019-12-31 |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs (NCT03896503) | National Cancer Institute (NCI) | 2019-12-30 |
| T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma (NCT04160195) | National Cancer Institute (NCI) | 2019-12-20 |
| Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study (NCT03872427) | National Cancer Institute (NCI) | 2019-12-14 |
| Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma (NCT03484819) | National Cancer Institute (NCI) | 2019-12-13 |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (NCT03816358) | National Cancer Institute (NCI) | 2019-12-09 |
| Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer (NCT03976843) | National Cancer Institute (NCI) | 2019-12-04 |
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927) | National Cancer Institute (NCI) | 2019-12-04 |
| Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (NCT03842228) | National Cancer Institute (NCI) | 2019-11-21 |
| Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (NCT03854474) | National Cancer Institute (NCI) | 2019-11-18 |
| Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers (NCT03801915) | National Cancer Institute (NCI) | 2019-11-13 |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (NCT03816332) | National Cancer Institute (NCI) | 2019-11-08 |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial (NCT03801902) | National Cancer Institute (NCI) | 2019-10-28 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (NCT03984448) | National Cancer Institute (NCI) | 2019-10-22 |
| Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma (NCT03910439) | National Cancer Institute (NCI) | 2019-10-17 |
| Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy (NCT03952598) | National Cancer Institute (NCI) | 2019-10-16 |
| Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia (NCT03196180) | National Cancer Institute (NCI) | 2019-10-15 |
| De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (NCT03952585) | National Cancer Institute (NCI) | 2019-10-09 |
| Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions (NCT03937791) | National Cancer Institute (NCI) | 2019-10-09 |
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (NCT03805932) | National Cancer Institute (NCI) | 2019-10-03 |
| Pediatric cGVHD Symptom Scale (NCT04044365) | National Cancer Institute (NCI) | 2019-10-02 |
| Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma (NCT03803774) | National Cancer Institute (NCI) | 2019-09-25 |
| Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer (NCT02595879) | National Cancer Institute (NCI) | 2019-09-18 |
| LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT04027946) | National Cancer Institute (NCI) | 2019-09-11 |
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (NCT03907488) | National Cancer Institute (NCI) | 2019-08-29 |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors (NCT04034238) | National Cancer Institute (NCI) | 2019-08-29 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (NCT03914612) | National Cancer Institute (NCI) | 2019-08-22 |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma (NCT03789240) | National Cancer Institute (NCI) | 2019-08-22 |
| A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma (NCT03880019) | National Cancer Institute (NCI) | 2019-08-19 |
| Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (NCT03811015) | National Cancer Institute (NCI) | 2019-08-16 |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) (NCT06400251) | National Cancer Institute (NCI) | 2019-08-08 |
| Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases (NCT02859415) | National Cancer Institute (NCI) | 2019-08-08 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (NCT04002947) | National Cancer Institute (NCI) | 2019-08-05 |
| A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer (NCT04044950) | National Cancer Institute (NCI) | 2019-07-29 |
| Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (NCT03811002) | National Cancer Institute (NCI) | 2019-07-26 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer (NCT03592641) | National Cancer Institute (NCI) | 2019-07-25 |
| Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (NCT03737994) | National Cancer Institute (NCI) | 2019-07-25 |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) (NCT06400225) | National Cancer Institute (NCI) | 2019-07-24 |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (NCT03907475) | National Cancer Institute (NCI) | 2019-07-16 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO (NCT03816345) | National Cancer Institute (NCI) | 2019-07-16 |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia (NCT03759184) | National Cancer Institute (NCI) | 2019-07-11 |
| Optimizing PTCy Dose and Timing (NCT03983850) | National Cancer Institute (NCI) | 2019-07-09 |
| CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (NCT03798678) | National Cancer Institute (NCI) | 2019-07-08 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (NCT03914625) | National Cancer Institute (NCI) | 2019-07-03 |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (NCT03964090) | National Cancer Institute (NCI) | 2019-06-27 |
| Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver (NCT03366155) | National Cancer Institute (NCI) | 2019-06-24 |
| Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma (NCT03856112) | National Cancer Institute (NCI) | 2019-06-21 |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT03772925) | National Cancer Institute (NCI) | 2019-06-20 |
| Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma (NCT03604978) | National Cancer Institute (NCI) | 2019-06-17 |
| T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma (NCT03958656) | National Cancer Institute (NCI) | 2019-06-13 |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (NCT03793166) | National Cancer Institute (NCI) | 2019-06-07 |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies (NCT03905135) | National Cancer Institute (NCI) | 2019-06-07 |
| The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk Tradeoffs (NCT02874053) | National Cancer Institute (NCI) | 2019-06-05 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (NCT03513952) | National Cancer Institute (NCI) | 2019-06-05 |
| Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (NCT03785210) | National Cancer Institute (NCI) | 2019-06-05 |